10x Genomics Beheer
Beheer criteriumcontroles 3/4
De CEO 10x Genomics is Serge Saxonov, benoemd in Jul2012, heeft een ambtstermijn van 12.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.29M, bestaande uit 6.6% salaris en 93.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.32% van de aandelen van het bedrijf, ter waarde $ 60.40M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 5.4 jaar.
Belangrijke informatie
Serge Saxonov
Algemeen directeur
US$8.3m
Totale compensatie
Percentage CEO-salaris | 6.6% |
Dienstverband CEO | 12.3yrs |
Eigendom CEO | 3.3% |
Management gemiddelde ambtstermijn | 2.8yrs |
Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Nov 0110x Genomics: Deciphering The Preliminary Q3 Earnings
Oct 12The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%
Oct 1110x Genomics Is Still A Long Way From Profitability
Oct 03We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Aug 1010x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Jul 1010x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Jun 21Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper
Jun 1410x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 22Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Sep 30 2024 | n/a | n/a | -US$183m |
Jun 30 2024 | n/a | n/a | -US$240m |
Mar 31 2024 | n/a | n/a | -US$264m |
Dec 31 2023 | US$8m | US$545k | -US$255m |
Sep 30 2023 | n/a | n/a | -US$223m |
Jun 30 2023 | n/a | n/a | -US$172m |
Mar 31 2023 | n/a | n/a | -US$174m |
Dec 31 2022 | US$19m | US$504k | -US$166m |
Sep 30 2022 | n/a | n/a | -US$167m |
Jun 30 2022 | n/a | n/a | -US$142m |
Mar 31 2022 | n/a | n/a | -US$89m |
Dec 31 2021 | US$12m | US$430k | -US$58m |
Sep 30 2021 | n/a | n/a | -US$455m |
Jun 30 2021 | n/a | n/a | -US$504m |
Mar 31 2021 | n/a | n/a | -US$533m |
Dec 31 2020 | US$11m | US$400k | -US$543m |
Sep 30 2020 | n/a | n/a | -US$134m |
Jun 30 2020 | n/a | n/a | -US$78m |
Mar 31 2020 | n/a | n/a | -US$49m |
Dec 31 2019 | US$2m | US$394k | -US$31m |
Sep 30 2019 | n/a | n/a | -US$100m |
Jun 30 2019 | n/a | n/a | -US$105m |
Mar 31 2019 | n/a | n/a | -US$105m |
Dec 31 2018 | US$1m | US$366k | -US$112m |
Compensatie versus markt: De totale vergoeding ($USD 8.29M ) Serge } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.57M ).
Compensatie versus inkomsten: De vergoeding van Serge is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Serge Saxonov (47 yo)
12.3yrs
Tenure
US$8,286,050
Compensatie
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 12.3yrs | US$8.29m | 3.32% $ 60.4m | |
Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 48.6m | |
Chief Legal Officer | 7.3yrs | US$3.88m | 0.12% $ 2.1m | |
CFO, Treasurer | less than a year | geen gegevens | geen gegevens | |
Chief of Global Operations | less than a year | geen gegevens | geen gegevens | |
Founding Scientist & CTO | 2.8yrs | geen gegevens | geen gegevens | |
Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
Manager of Investor Relations & Strategic Finance | no data | geen gegevens | geen gegevens | |
Chief People Officer | 3.8yrs | geen gegevens | geen gegevens | |
Chief Commercial Officer | less than a year | geen gegevens | geen gegevens | |
Associate Director of Product Management | no data | geen gegevens | geen gegevens |
2.8yrs
Gemiddelde duur
48.5yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van TXG wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
Co-Founder | 12.3yrs | US$8.29m | 3.32% $ 60.4m | |
Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 48.6m | |
Independent Director | 4.7yrs | US$338.71k | 0.0038% $ 69.2k | |
Independent Chairman | 11.3yrs | US$403.59k | 2.02% $ 36.6m | |
Independent Director | 5.3yrs | US$336.39k | 0.0038% $ 69.2k | |
Director | less than a year | geen gegevens | geen gegevens | |
Independent Director | 5.6yrs | US$346.39k | 0.029% $ 532.0k | |
Director | less than a year | geen gegevens | geen gegevens |
5.4yrs
Gemiddelde duur
52yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van TXG wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).